L-carnitine Could Be Beneficial in Nonalcoholic Fatty Liver Disease Patients by Improving Choline Metabolism and Reducing Liver Biomarkers - European Medical Journal

L-carnitine Could Be Beneficial in Nonalcoholic Fatty Liver Disease Patients by Improving Choline Metabolism and Reducing Liver Biomarkers

2 Mins
*Dragana Savic,1 Michael Pavlides,1,2 Vicky Ball,3 Lisa Heather,3 Damian Tyler1,3

The authors have declared no conflicts of interest.


The authors wish to thank Drs Kate Curtis and Kerstin Timm for their help with animal handling and blood sampling, Prof Jules Griffin and Dr James West for their metabolomic service at the Department of Biochemistry, University of Cambridge, UK, and finally Prof Stefan Neubauer and Prof Leanne Hodson for their supervision and expertise in  liver metabolism.

EMJ Hepatol. ;7[1]:47-48.
Alanine transaminase (ALT), aspartate transaminase (AST), choline, choline deficiency, fatty liver disease, L-carnitine, liver metabolites, metabolomics, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH).

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Nonalcoholic steatohepatitis (NASH) patients have reduced levels of choline in the liver.1 Choline metabolism is critical in maintaining normal liver function2 and is important in the synthesis of very-low-density lipoproteins from triglycerides (TAG) in the liver.3 Choline is also important for normal kidney and mitochondrial function.4 Choline deficiency will lead to an accumulation of liver TAG levels, resulting in elevated lipid levels. Furthermore, choline can be oxidised to betaine, which is an important methyl donor and participates in the methionine cycle in the liver. Methionine, together with lysine, forms L-carnitine in the liver and kidneys.

L-carnitine is critical for the transportation of long-chain fatty acids. NASH patients display abnormal parameters in liver function tests, such as elevated levels of aspartate transaminase (AST) and alanine transaminase (ALT);5 however, L-carnitine has been shown in several studies to improve liver function in NASH patients and prevent the progression of the disease.6–8

This study investigated what effect L-carnitine supplementation could have on liver metabolites. In this study, the authors hypothesised that L-carnitine could elevate choline in the liver through a regulation of betaine. Furthermore, they aimed to investigate liver function to understand how L-carnitine affects key liver enzymes.

A total of 16 healthy male Wistar rats (approximately 200 g) were treated daily with either saline (n=8) or L-carnitine (n=8; intra-peritoneal injections, 3 g/kg/day) for 2 weeks. Following treatment, body weight was measured and blood obtained, before euthanasia and extraction of liver tissue  for metabolomic analysis. Liver tissue was crushed and prepared with previously described methods to separate the aqueous, lipid, and protein layers,9 and sent to the Department of Biochemistry at the University of Cambridge, Cambridge, UK, where liquid chromatography mass spectrometry was undertaken.

The L-carnitine-treated group had 15% lower body weight (p<0.01) and 55% reduced serum TAG levels compared to the saline-treated group. L-carnitine resulted in higher liver choline levels (47%; p=0.05) and reduced levels of betaine (24%; p=0.04). Alanine was elevated in the liver by a factor of 76.6, while oxaloacetate was elevated by a factor of 1.3 following L-carnitine treatment compared to saline treatment. Pyruvate, α-ketoglutarate, glutamate, and aspartate all stayed constant between the two groups (Figure 1).

Figure 1: Liver function measured in the saline (Sal) treated group and L-carnitine (Carn) treated group.

All data presented as mean+standard deviation, significant values presented as *p<0.05 and ****p<0.0001 Metabolites relevant for alanine transaminase and aspartate transaminase measured with metabolomics (μmol/gww).

Metabolism in the liver was modulated by L-carnitine. The liver is critical for choline metabolism, and studies have shown that NASH is associated with lower choline concentrations. This study demonstrated that some of the beneficial effects of L-carnitine could be mediated through increased liver choline levels, possibly by an elevation of betaine, which was reduced in the liver when treated with L-carnitine. In addition, L-carnitine improved the AST/ALT ratio, which is commonly used to assess liver damage, where an elevation signifies advancement of fibrosis.10 L-carnitine elevatedalanine levels considerably more so than it elevated oxaloacetate, forcing the AST/ALT ratio to reduce, and thereby improving liver function.  Future studies should investigate liver enzymes and metabolites in NASH patients treated with L-carnitine, which could help elucidate the mechanism through which L-carnitine can prove beneficial toliver function and provide insights into novel therapeutics.

Spencer MD et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011;140(3):976-86. Mehedint MG, Zeisel SH. Choline’s role in maintaining liver function: New evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013;16(3):339-45. Leung C et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412-25. Zeisel SH. Choline: Critical role during fetal development and dietary requirements in adults. Annu Rev Nutr. 2006;26:229-50. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J. Postgrad Med J. 2003;79(932): 307-12. Malaguarnera M et al. L-carnitine supplementation to diet: A new tool in treatment of nonalcoholic steatohepatitis--A randomized and controlled clinical trial. Am J Gastroenterol. 2010;105(6):1338-45. Bae JC et al. Improvement of nonalcoholic fatty liver disease with carnitine-orotate complex in Type 2 diabetes (CORONA): A randomized controlled trial. Diabetes Care. 2015;38(7):1245-52. Alavinejad P et al. Evaluation of L-carnitine efficacy in the treatment of non-alcoholic fatty liver disease among diabetic patients: A randomized double blind pilot study. J Gastroenterol Hepatol Res. 2016;5(5). Roberts LD et al. Methods for performing lipidomics in white adipose tissue. Methods Enzymol. 2014;538:211-31. Malakouti M et al. Elevated liver enzymes in asymptomatic patients - What should I do? J Clin Transl Hepatol. 2017;5(4):394-403.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now